For patients with EGFR-mutated resected NSCLC, a new, more effective, and better tolerated treatment option exists with oral osimertinib, making for this patient population the role of adjuvant chemotherapy less relevant and also more difficult to explain and comprehend. This evidence concerns the gene EGFR and non-small cell lung carcinoma.